UPDATE 1-FDA staff questions Clovis drug's benefit over current treatments

April 8 (Reuters) - The U.S. Food and Drug Administration

staff reviewers on Friday questioned whether Clovis Oncology

Inc's lung cancer drug was superior to existing

treatments.

Read more